Engineering of Inflammation-Resistant Osteochondral Cells by Gordeladze, Jan O. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 20
Engineering of Inflammation-Resistant
Osteochondral Cells
Jan O. Gordeladze, Janne E. Reseland,
Tommy A. Karlsen, Rune B. Jakobsen,
Astrid K. Stunes, Unni  Syversen, Lars  Engebretsen,
Ståle P. Lyngstadaas and Christian Jorgensen
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/55544
1. Introduction
1.1. Clinical issue
Osteoblasts and chondrocytes engineered from various sources of stem cells to replace dam‐
aged bone or cartilage in an inflamed joint in patients with inflammatory diseases like osteoar‐
thritis or osteoarthrosis need to be made resilient to the impact of the inflamed environment
within the joint cavity (Neve, Corrado et al. 2011; van der Kraan and van den Berg 2012). Clinical
experience has clearly shown that the engineered osteochondral cells relatively quickly tend to
lose their defined cell phenotype (Chen and Tuan 2008; Kastrinaki and Papadaki 2009), while
also tending to perpetuate bone loss through activation of osteoclasts, thus yielding a negative
bone remodelling volume (Lories 2011; Goldring 2012). The present concept of manipulation of
stem cell microRNA levels envisages one route, by which one may obtain engineered osteochon‐
dral cells with a better potential of producing bone and cartilage in vivo, and to withstand the
putative detrimental effect of immune cell (e.g. T-helper cell = Th-cell) influence constituted by
a plethora of cytokines and exosome-conveyed microRNAs.
1.2. Previous findings
We have previously shown that osteochondral cells can be derived from human mesenchymal
stem cells (hMSCs) by manipulating the levels of a group of microRNAs, i.e. mir-16, mir-24,
mir-125b, mir-149, mir-328, and mir-339 (Gordeladze 2009; Gordeladze, Djouad et al. 2009). All
© 2013 Gordeladze et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
these microRNAs are low in differentiated osteoblasts, but highly expressed in stem cells and
differentiated chondrocytes. Especially mir-149 seems to serve as a switch, both stimulating
chondrogenesis,  while  suppressing  osteoblastogenesis  in  differentiating  hMSCs.  Further‐
more, mir-328 and mir-339 are the better determinants of the osteochondral cell phenotypes,
since manipulations of their intracellular levels enabled us to reciprocally trans-differentiate
osteoblasts to chondrocytes at day 7-14 in 2D and 3D cultures in vitro (Gordeladze, Djouad et al.
2009; Gordeladze 2011). Hence, we propose that these six microRNAs, and mir-149, mir-328,
and mir-339 in particular, might be able to influence the osteochondral phenotypes in such a
way that they are able to maintain their phenotype in vitro and in vivo for an extended period of
time, while under the influence of a Th-cell invaded arthritic luminal space.
1.3. Experimental procedures
The material used in a defined set of experiments consisted of hMSCs differentiated towards
osteoblasts in monolayer cultures or in scaffolds (hydroxyapatite or alginate beads, respec‐
tively), hPBMCs (human peripheral blood monocytic cells) differentiated towards osteoclasts
and grown on bovine dentine slices, exosomes (100,000xg pellets) from activated Th-17 cells,
and SCID mice. The cells were transfected with scrambled microRNA, mir-16, mir-24,
mir-125b, mir-149, mir-328 or mir-339 pre-microRNAs or antago-microRNAs, using amounts
known to suppress or enhance endogenous levels approximately 5 times (Gordeladze 2009).
Human MSCs, osteoblasts or chondrocytes were grown in a medium supplemented with
chemokines (Interleukin-1 = IL-1, Interleukin-6 = IL-6, and Interleukin-17A = IL-17A, and
TNFα), or over-layered with exosomes from Th17 cells, either in the absence or presence of
dentine slices over-layered with osteoclasts differentiated from hPBMCs, using RANK-L and
M-CSF (Fritz, Brondello et al. 2011). Subsequent to a certain period of time (7-21 days),
osteochondral cells were either analysed for phenotypic characteristics (e.g. matrix production,
microRNA levels, phenotypic gene expression) or injected (without or with mature osteoclasts)
into the tibial muscle of SCID mice. After 14 days of in vivo incubation, the de novo formed
osteochondral tissues were analysed for phenotypic markers of injected cells by Q-PCR, as
well as matrix characteristics (e.g. matrix protein immunohistochemistry, hydroxyapatite
production, or GAG = glucosaminglycan over DNA ratio).
1.4. Results
These experiments showed the following:
1. Human MSCs, pre-chondrocytes or pre-osteoblasts lost many of their phenotypic
characteristics as matrix builders upon exposure to either pre-microRNAs (osteoblasts)
or antago-microRNAs (chondrocytes).
2. These cells, when grown in co-culture with differentiated osteoclasts, appeared to enhance
osteoclast multi-nucleation, gene expression, and ensuing dentine resorption surface area.
3. By exposing these cells to either artificial, i.e. “inflamed” synovial fluid (growth medium
fortified with Th17 cell like profile of cytokines), exosome-like fractions obtained from
activated Th17 cells, or certain pre-microRNAs (i.e. mir-222 for chondrocytes or mir-22
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for osteoblasts), we observed that the osteochondral phenotypes were disturbed, along
with a concomitantly enhanced potential for osteoclast activation.
4. Growing hMSCs in a 3D structure (hydroxyapatite for osteoblasts and soft alginate beads
for chondrocytes) also stabilized phenotypic characteristics, though to a lesser degree.
5. Injecting manipulated osteochondral cells with or without a certain number of pre-
differentiated osteoclasts into the tibial muscle of SCID mice yielded de novo formed bone
and cartilage tissues, where more than 95% of the injected cells resided within the newly
formed tissues. Parameter evaluation (histology, immuno-histochemistry of collagens
and aggrecan, X-ray analysis, GAG/DNA ratio, estimation of total Ca2+-contents, and Q-
PCR analyses of marker genes) of the osteochondral cells, as well as Q-PCR analyses of
osteoclast marker genes (like the calcitonin receptor, TRAP, cathepsin K, and carbonic
anhydrase II) clearly showed that either of the de novo formed tissues were not functioning
optimally, and that enhanced osteoclast activation prevailed.
6. Interestingly, cells having been transfected with optimal amounts of either pre-micro‐
RNAs or antago-microRNAs maintained their phenotypic characteristics within the tibial
muscle of SCID mice, even when pre-exposed to the “inflammation”-mimicking medium
or exosome-like particles from activated Th17 cells.
7. Polycistronic vector constructs containing the pre- and antago-microRNAs 149, 328, and
339 are now being made to verify the benefit of controlling the endogenous levels of these
microRNA species to produce stable osteochondral phenotypes to be implemented in in
vitro and in vivo animal model systems.
1.5. Conclusion
Manipulating pertinent microRNAs in osteoblast or chondrocytes derived from hMSCs (or
other sources, such as hADSCs = human adipose tissue derived stem cells) may facilitate
differentiation to proper, functional cell phenotypes, which are also resilient to the detrimental
impact from inflammatory chemokines and/or microRNAs, proteins or mRNAs transferred
from Th-cells (via exosome-like vehicles) to engineered osteoblasts or chondrocytes.
2. Bone remodelling
2.1. Cellular and molecular mechanisms of bone remodelling
Physiological remodelling of bone has proven to be a highly coordinated process constituted
by bone resorption following bone formation, and it is necessary for damaged bone to be
repaired, and to maintain mineral homeostasis (Mackie, Ahmed et al. 2008; Kular, Tickner et
al. 2012; Thompson, Rubin et al. 2012). In addition to the traditional cells localized within the
bone tissue (i.e. osteoclasts, osteoblasts, and osteocytes) necessary for completion of multiple
bone remodelling cycles, several classes of immune cells have also been implicated in bone
turnover and also bone disease states (Chen and Tuan 2008; Lories 2011; Mellis, Itzstein et al.
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2011; Sims and Walsh 2012). The two processes of modelling and remodelling ensure proper
development and maintenance of the skeletal system. The process of bone modelling is
mandatory for growth and mechanically induced adaption of bone (Kular, Tickner et al.
2012; Thompson, Rubin et al. 2012), but it requires that the processes of bone formation and
bone resorption (removal of “old” bone with micro-fractures) occur independently, and at
distinct locations within the skeleton (Chang, Raggatt et al. 2008; Raggatt and Partridge 2010;
Kular, Tickner et al. 2012). These tightly coordinated events require the synchronized activities
of multiple cellular participants and compartments, in order to ensure that bone resorption
and formation occur sequentially within the same anatomical locations to preserve bone mass
with a functional geometry.
Figure 1. Schematic representation of a previously published microRNA profile distinguishing between osteoblasts
and chondrocytes differentiated from human mesenchymal stem cells (hMSCs). Right hand frame: The six microRNA
species have been proven to bind to and suppress the transcription of genes encoding nine factors deemed important
for osteoblastogenesis, i.e. SATB2, HES-1, ETS-1, RUNX2, APC2, OSTERIX, VDR, LEF-1, and RNF11 (Marie 2008; Gorde‐
ladze, Djouad et al. 2009). Left hand frame: Interestingly, the microRNA species mir-24, and especially mir-149, may be
regarded as important “switches” between the osteoblast and chondrocyte phenotypes, since they both positively
suppress transcription factors (TFs), as predicted by using the MirnaViewer and the Sanger algorithms, necessary for
osteoblastogenesis, and at the same time negatively affect factors (like ATF4, PIAS1, STAT6, and PPPIR6B) (Legendre,
Dudhia et al. 2003; Komatsu, Mizusaki et al. 2004; Oh, Kido et al. 2007; Suzuki, Osumi et al. 2010), which serve as
inhibitors of Sox9 expression, deemed as the most important TF initiating chondrocytogenesis and maintaining the
chondrocyte phenotype.
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2.2. Cells being involved in bone remodelling
Osteoblasts - Osteoblasts are specialized bone-forming cells responsible for many of the crucial
functions constituting bone remodelling (i.e. expression of osteoclastogenic factors, production
of bone matrix proteins, and bone mineralization) (Karsenty 2008). The stage of differentiation
acquired by the osteoblasts influences the functional contribution to and impact of these cells
on in vivo bone remodelling. Immature pre-osteoblasts influence osteoclastogenesis, while
mature osteoblasts are responsible for matrix production and mineralization. Osteoblasts
develop from pluripotent hMSCs, which exhibit inherent potential to develop into adipocytes,
myocytes, chondrocytes, and osteoblasts orchestrated by a series of defined transcription
factors (TFs). Osteoblast differentiation has since long been reported to be controlled by
RUNX2, but several other TFs are now recognized as equally important for osteoblastogenesis
(Franceschi, Xiao et al. 2003). It has been published that 14 different TFs (and/or modulatory
proteins), including SATB2, HES-1, ETS-1, LEF-1, SP7 (OSTERIX), RNF11, VDR, and APC2 (a
positive regulator of β-catenin of the canonical WNT-pathway) define the differentiating
potential of osteoblasts with a statistical extremely high probability (p = 2α < 5x10-13) (Gorde‐
ladze, Djouad et al. 2009).
Figure 2. Putative interactions between transcription factors (TFs), microRNA species, and functional genes de‐
scribing: (A). Hierarchical feed-forward regulation by MYC (Myc proto-oncogene protein) and JUN (transcription fac‐
tor AP-1) of the canonical WNT-system (important for osteoblastogenesis), including factors like SMAD3 (modulator
of TCF/LEF), SFRP1 (secreted frizzled-related protein 1), CCND1 (Cyclin D1), LRP5 (low density lipoprotein receptor-re‐
lated protein 5), hsa-mir-339, hsa-mir-328, and hsa-mir-149 directly, while CCND2 (cyclin D2), GSK3B (glycogen syn‐
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thase kinase 3β), NKD2 (naked cuticle 2), CTNNBIP1 (catenin β1), and WNT3 (wingless-type MMTV integration site
family, member 3) are affected indirectly. (B). Hierarchical feed-forward regulation by ETS1 (a stimulator of CCN2 =
connective tissue growth factor, a mediator of TGFβ1-mediated matrix protein synthesis in osteoblasts) and SP3 by
microRNA species including hsa-mir-339, hsa-mir-149, and hsa-mir-328. The TF RNF11, which has now received in‐
creasing attention as a major modulator of osteoblastogenesis (Gao, Ganss et al. 2005), is directly affected by hsa-
mir-149. (C). Hierarchical (and possibly superior) feed-forward regulation by Sox9 of STAT1- and EGR2-mediated
transcription of the micro-RNA species mir-149 and mir-328. EGR2/KROX-2 (a transcription factor stimulated by
WNT3) exerts a major impact on mir-149 and mir-328, which directly affect the transcription of genes like PRRX1,
AKT3, TBX2, SLC14A1, NOTCH3, FKBP5, BDNF, and DLX3 (as predicted using the MirnaViewer and Sanger algorithms.
Of these genes, PRRX1 is a regulator of OSTERIX, AKT3 and RUNX2 (Lu, Beck et al. 2011) where all are mutually in‐
volved in osteoblast differentiation, TBX2 is required for osteoblast proliferation, NOTCH3 inhibits osteoblast differen‐
tiation(Lin and Hankenson 2011), FKBP5 overexpression is known to ensure osteoblast differentiation from hMSCs,
BDNF is involved in endochondral ossification (Yamashiro, Fukunaga et al. 2001; Marie 2008), and DLX3 is well known
as an early inducer of osteoblast differentiation co-acting with RUNX2, DLX5, and MSX2 (Heining, Bhushan et al.
2011). This particular scheme of interactions emerged when combining an osteoblast microRNA micro-array with
published osteoblast mRNA transcriptomes (Gordeladze 2011). The bioinformatics modulations are performed by us‐
ing the algorithm Mir@nt@n (Le Bechec, Portales-Casamar et al. 2011) with standard stringent conditions for putative
modulations of gene expression. As the reader will notice, a few other microRNA species may also have been selected
to be included amongst the six microRNAs constituting the present osteochondral signature.
Osteocytes - During the course of bone formation, a sub-population of osteoblastic cells
undergoes terminal differentiation and becomes engulfed within unmineralized osteoid. They
are referred to as osteocytes (Palumbo 1986). Following the mineralization phase, these
entombed cells form a network which extends throughout the mineralized bone tissue.
Osteocytes respond to mechanical load (mechano-stimulation), and their network is believed
to integrate the detection bone micro-damage (micro-fractures within the mineralized bone),
which accumulates as a result of normal skeletal loading and fatigue (Verborgt, Tatton et al.
2002). Data have been obtained that support the idea that osteocytes initiate and direct the
subsequent remodelling process that repairs damaged bone. Furthermore, the osteocytes have
been hypothesized to serve as sensors for the nervous system connected to the skeleton, and
for instance convey hypothalamus-derived nerve impulses driven by leptin receptors as a feed-
back regulatory loop controlling bone mass (i.e. bone turnover) within optimal limits
(Takarada and Yoneda 2008; Thompson, Rubin et al. 2012; Motyl and Rosen 2012).
T-cells and B-cells - T-lymphocytes and B-lymphocytes serve as central players of the adaptive
immune system facilitating the recognition and the destruction of pathogenic microorganisms.
Mice, which are devoid of either B- or T-lymphocytes exhibit osteoporosis, indicating that these
immune cells are routinely participating in the maintenance of bone homeostasis (Li, Toraldo
et al. 2007). Mature B-cells produce ~50% of total bone marrow-derived OPG, which would
contribute significantly to the restraint of osteoclast differentiation and activation during
normal bone turnover. However, the role of T-cells in regulating bone remodelling during
homeostasis is less clear. Based on data that T-cell-deficient CD40 knock-out and CD40L knock-
out mice are osteoporotic (Li, Toraldo et al. 2007), it has been proposed that T-cells work
cooperatively with B-cells and enhance OPG production via CD40/CD40L co-stimulation
(Raggatt and Partridge 2010)
Osteomacs - Osteomacs are defined as tissue macrophages residing on on or within the
endosteal and/or periosteal surfaces. In vitro, osteomacs are required to ensure full functional
differentiation of the osteoblast, i.e. the acquisition of mineralizing properties, which consti‐
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tutes the late phase of the osteoblasts’ life span. In vivo, osteomacs form a canopy over mature
matrix-producing osteoblasts at sites of bone modelling, which serves as an ideal anatomical
location from which to regulate such a process. A depletion of macrophages in vivo inevitably
leads to a complete loss of endosteal osteomacs and associated osteoblasts, indicating that the
osteomacs are needed to sustain osteoblast maturation and mineralizing property (Chang,
Raggatt et al. 2008).
Osteoclasts - Osteoclasts are terminally differentiated myeloid derived cells, being adapted to
excavate mineralized osteoid (bone matrix). These particular cells exhibit distinct morpholog‐
ical and phenotypic characteristics routinely used as functional markers. They include
multinuclearity and expression of tartrate-resistant acid phosphatase (TRAP) and the calcito‐
nin (CT) receptor (Teitelbaum and Ross 2003). M-CSF (macrophage colony-stimulating factor)
and RANK-L (receptor activator of NFκ-B ligand) serve as critical cytokines being required
for the survival, expansion, and the differentiation of osteoclast precursors (hPBMCs = human
peripheral blood monocytic cells) in vitro (Lacey, Timms et al. 1998). The requirement of these
cytokines for osteoclast induced bone resorption in vivo, has been demonstrated in animal
model systems lacking functional M-CSF and RANK-L. The molecule OPG-2 (osteoproteger‐
in-2) serves as a soluble decoy receptor for RANK-L and a negative physiological regulator of
osteoclastogenesis, i.e. loss of functional OPG in mice, results in osteoporosis, due to excessive
induction (or differentiation) and activation of osteoclasts (Simonet, Lacey et al. 1997). The
current paradigm asserts that the RANK-L/OPG expression ratio determines the degree of the
osteoclasts’ biological activity (i.e. their differentiation and function) (Hofbauer, Khosla et al.
2000). Several TFs, like FOS, MYC, AP-1 (JUN), PU.1, and CREB (Tondravi, McKercher et al.
1997) are deemed necessary to differentiate myeloid cells toward the osteoclast phenotype.
MITF (microphthalmia-associated transcription factor) and NFATc1 (nuclear factor of
activated T-cells, cytoplasmic 1), which is also important for hMSCs to develop into the
osteoblastic lineage (Marie 2008) are also required for osteoclast formation and their expression
of osteoclast-specific genes like TRAP (Luchin, Purdom et al. 2000), cathepsin K, and the CT
receptor (Matsumoto, Kogawa et al. 2004; Hu, Sharma et al. 2007).
2.3. The process of bone remodelling
Prior to activation, the resting bone surface is covered with bone-lining cells, including pre-
osteoblasts intercalated with osteomacs. B-cells are present in the bone marrow and secrete
OPG, which suppresses osteoclastogenesis (Raggatt and Partridge 2010).
Activation: The endocrine bone-remodelling signal PTH binds to the PTH receptor on pre-
osteoblasts. Damage to the mineralized bone matrix results in localized osteocyte apoptosis,
reducing the local TGF-β concentration and its inhibition of osteoclastogenesis (Juppner,
Abou-Samra et al. 1991; Heino, Hentunen et al. 2002; Swarthout, D'Alonzo et al. 2002; Verborgt,
Tatton et al. 2002; Aguirre, Plotkin et al. 2006; Bonewald 2007; Weitzmann and Pacifici 2007).
Resorption: In response to PTH signalling, monocyte chemotactic protein (MCP-1) is released
from osteoblasts and recruits pre-osteoclasts to the bone surface. Additionally, osteoblast
expression of OPG is diminished, and production of M-CSF and RANK-L is increased, in order
to promote proliferation of osteoclast precursors (hPBMCs) and differentiation of mature
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osteoclasts. The mature osteoclastic cells become anchored to RGD-binding sites (Arg-Gly-Asp
containing proteins), creating a localized micro-environment (i.e. a sealed zone) facilitating the
degradation of mineralized bone matrix (Partridge, Jeffrey et al. 1987; Insogna, Sahni et al.
1997; Saftig, Hunziker et al. 1998; Burgess, Qian et al. 1999; McHugh, Hodivala-Dilke et al.
2000; Teitelbaum 2000; Ma, Cain et al. 2001; Yang, Chien et al. 2004; Li, Qin et al. 2007).
Reversal: So called reversal cells engulf and destroy demineralised, undigested collagen from
the bone surface. Transition signals are generated for the purpose of halting bone resorption
and to stimulate the process of bone formation(Tran Van, Vignery et al. 1982; Kraal, Rep et al.
1987; Heinemann, Siggelkow et al. 2000; Everts, Delaisse et al. 2002; Takahashi, Takahashi et
al. 2004; Newby 2008).
Formation: Signalling molecules stimulating bone formation arise from degraded bone matrix,
mature osteoclastic cells, and potentially also reversal cells. PTH-binding to and mechano-
stimulation of osteocytes reduce the expression and secretion of sclerostin (an inhibitor of
BMP-binding to its receptor), allowing Wnt-stimulated bone formation to occur (Fermor and
Skerry 1995; Harmey, Hessle et al. 2004; van Bezooijen, Roelen et al. 2004; Li, Zhang et al.
2005; Martin and Sims 2005; Murshed, Harmey et al. 2005; Zhao, Irie et al. 2006; Pederson,
Ruan et al. 2008; Robling, Niziolek et al. 2008; Tang, Wu et al. 2009).
Figure 3. The impact of pre-microRNA and antago-microRNA species of the osteochondral microRNA signature on the
differentiation of osteochondral cells from hMSCs. The following parameters were analysed: endogenous microRNA
levels, and average alteration in various differentiation markers. MicroRNA levels and marker gene mRNAs (Collagens,
Gli3, Sox9, Osteocalcin, and Runx2) were analysed using the Q-PCR method (Ambion). Estimations of GAG/DNA-ratio
(chondrocytes only) were performed using colorimetric methods. Mineralized surface calculations in osteoblast cul‐
tures were achieved using the Alizarin red S staining method (Gordeladze, Noel et al. 2008)
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Figure 4. A. Co-culture of chondrocytes in alginate beads (or osteoblasts in 2D culture) in standard medium
(Gordeladze 2011). Osteochondral cells were differentiated from hMSCs in appropriate medium for 14 days. Then, a
dentine slice, with close to 100% enriched peripheral blood monocytes (PBMCs) had been differentiated for 14 days
with RANKL-L and M-CSF, was placed adjacent to the osteochondral cells, and both cell types were co-cultured for 7
days. At the end of the experiment, the number of TRAP-positive cells was counted, and the eroded dentine surface
(%) was estimated in a reflecting light microscope. B. Co-culture of chondrocytes in alginate beads (or osteoblasts in
2D culture) in standard medium (Gordeladze 2011). The subject experimental setting was also applied to differentiat‐
ing osteoblast. Here, we used the cytokine mixture as described in (B), and antago-microRNAs counteracting the os‐
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teochondral signature. Variables analysed were much like those for the experiment with chondrocytes. However, here
we measured mineralizing surface (Alizarin red S coloration) induced by the osteoblasts in a 2D culture.C. Co-culture
of chondrocytes in alginate beads (or osteoblasts in 2D culture) in standard medium (Gordeladze 2011). The above
mentioned experimental setting was used with chondrocytes differentiated from hMSCs in alginate beads in the ab‐
sence or presence of cytokines (IL-1, IL-6, IL-17, and TNFα), pre-microRNAs of all microRNA species of the osteochon‐
dral signature, or the set of cytokines along with the pre-microRNAs. Parameters analysed were: Q-PCR of
transcription factors (TFs) and marker genes expressed by the chondrocytes, clinical score of alginate beads containing
chondrocytes embedded in newly synthesized proteoglycan matrix, the number of Trap-positive osteoclasts, and the
eroded dentine surface (%).
Termination: Sclerostin expression then fades or ceases, and the process of bone formation
comes to a halt. The newly deposited osteoid is subsequently mineralized, the bone surfaces
return to their resting state, This is when bone-lining cells intercalate with osteomacs, and
the remodelling cycle is concluded (Raggatt and Partridge 2010).
3. Osteoclast differentiation and activation
3.1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease perpetuated by a dysregulated
immune system. The cause remains grossly unknown, however both environmental and
genetic factors are believed to contribute to RA development (Kochi 2010; Boissier 2011). The
disease is characterized by joint inflammation, initially resulting in pain and swelling, and in
a majority of the patients, erosion of bone and cartilage takes place (Lories 2011). The goal of
current treatment regimens is to control inflammation, as well as to halt or retard the progres‐
sion of damage of the bone structure of the affected joint(s), as measured by X-ray analysis
(Tan and Conaghan 2011). The RA joint, synovial fluid, and synovium contain a large variety
of hematopoietic cells, which are situated in direct proximity to the articular cartilage and its
underlying bone structures (Carvalheiro, da Silva et al. 2012; Shegarfi, Naddafi et al. 2012).
Hence, the synovial fluid with its contents of immune cells and cytokines secreted from the
cells in question, undoubtedly are responsible for the joint-destructive process (Iwamoto,
Okamoto et al. 2008; Yamada, Nakashima et al. 2008).
3.2. Osteoclast differentiation
Physiological and pathological bone resorption is achieved by the osteoclast. Osteoclasts are
large 20 to 100 μm multinucleated cells containing from three to 100 nuclei with many
mitochondria, lysosomes, dense granules, vesicles, and an extensive Golgi network required
for the synthesis and secretion of factors required to degrade bone matrix and subsequently
phagocytose the resorbed products (Holtrop and King 1977). Tartrate-resistant acid phospha‐
tase (TRAP) (Minkin 1982), cathepsin K (Drake, Dodds et al. 1996), the calcitonin (CT) receptor
(Hattersley and Chambers 1989), as well as αvβ3 integrin (Davies, Warwick et al. 1989) are
marker gene products of the mature osteoclast (Teitelbaum 2000). The initial event in bone
resorption is the attachment of the mature osteoclast to the bone matrix. Cell surface αvβ3
integrins bind to a plethora of extracellular matrix proteins synthesized and secreted by
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osteoblastic cells, including vitronectin, osteopontin, and bone sialoprotein. Arg-Gly-Asp-
containing peptides, Arg-Gly-Asp mimetics, and blocking antibodies to αvβ3 integrins have
been shown to inhibit bone resorption, both in vitro and in vivo, indicating that this integrin
plays a pivotal role in osteoclast functioning (Horton, Taylor et al. 1991). Once attached to bone,
the osteoclast generates an isolated extracellular, acidic microenvironment between itself and
the bone surface by creating a sealing zone structure unique to the osteoclast.
3.3. Osteoclast activation
As described in a previous paragraph, macrophage CSF (M-CSF) and receptor activator of
NFκB ligand (RANK-L) are the most important factors known to date to drive osteoclast
formation and activity (Lacey, Timms et al. 1998; Quinn, Elliott et al. 1998). M-CSF serves as a
survival factor for osteoclast precursors due to up-regulation of Bcl-XL, inhibition of caspase-9
activation (Woo, Kim et al. 2002), and the support of mature osteoclast survival by preventing
apoptosis (Fuller, Owens et al. 1993). Exposure to M-CSF also stimulates receptor activator of
NFκB (RANK) expression in osteoclast precursor cells, thereby allowing RANK-L to drive
formation of mature osteoclasts (Arai, Miyamoto et al. 1999). RANK-L is a trans-membrane
protein expressed by activated osteoblasts, synovial fibroblasts, as well as T-cells. It can also
be proteolytically cleaved by TNF convertase (TACE) to generate a soluble molecule that has
osteoclastic activity at distal sites (Hofbauer, Khosla et al. 2000; Li, Toraldo et al. 2007). RANK-
L induced osteoclastogenesis is inhibited by OPG (osteoprotegerin), a soluble decoy receptor
for RANKL, which is also produced by a variety of cells including osteoblasts, synovial
fibroblasts, B-cells, and T-cells (Simonet, Lacey et al. 1997; Hofbauer, Khosla et al. 2000;
Takayanagi, Iizuka et al. 2000; Gillespie 2007; Li, Toraldo et al. 2007). In the arthritic joint, there
is a significant macrophage infiltrate, and the extent of the subject infiltration correlates heavily
with the extent of joint erosion in both RA patients and animal models with arthritis (Yanni,
Whelan et al. 1994). Synovial macrophages isolated from different types of arthritis may
differentiate in vitro to fully functional osteoclasts subsequent to RANK-L stimulation as well
as independently of the RANK/RANK-L signalling pathway, i.e. after short term exposure to
TNFα and IL-1α (Adamopoulos, Sabokbar et al. 2006). Stimulatory, co-stimulatory, and/or
inhibitory signals may be provided by adjacent T-cell species present in the inflammatory
infiltrate.
4. T-cell subsets and their action on osteoclasts
4.1. Th17 cells versus Th1 and Th2 cells
The Th17 lineage has only recently been fully characterized (Adamopoulos and Bowman
2008) and the factors involved in its differentiation are still being identified and sorted out
(Hirota, Hashimoto et al. 2007; Parsonage, Filer et al. 2008). When a (CD4+) naïve T cell is
activated in the presence of transforming growth factor beta (TGFβ) plus IL-6 in the mouse or
TGFβ plus an inflammatory stimulus in the human, the resulting clonal memory T-cell
population will be instructed to produce the Th17 signature cytokines IL-17A, IL-17F, IL-22,
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and (only in humans) IL-26 (Manel, Unutmaz et al. 2008). The inflammatory stimuli in the
human setting can be IL-1β, IL-6, IL-21, and/or IL-23 (Langrish, Chen et al. 2005; Acosta-
Rodriguez, Napolitani et al. 2007; Wilson, Boniface et al. 2007; Manel, Unutmaz et al. 2008;
Volpe, Servant et al. 2008; Yang, Anderson et al. 2008). IL-17A is the only Th17 signature
cytokine presently known to impact osteoclast biology. Synovial residing and synovial fluid
derived macrophages are able to differentiate to fully functional bone-resorbing osteoclasts,
and Th17- induced synovial macrophage–mediated osteoclast differentiation is believed to
represent an important mechanism in bone destruction associated with rheumatoid arthritis
(Fujikawa, Sabokbar et al. 1996; Adamopoulos, Sabokbar et al. 2006). Several types of IL-17A
antagonists have been applied in a variety of experimental arthritis models to elucidate the
efficacy of therapeutic IL-17A neutralization. Polyclonal anti-IL-17A antibody treatment after
disease induction in the collagen induced arthritis (CIA) model diminished clinical scores
subsequent to 10 days of therapy, compared with controls. Ankle and knee joints displayed
reduced synovitis, cartilage destruction, chondrocyte cell death, depletion of proteoglycans,
and bone erosion (estimated by both histology and X-ray analyses) (Lubberts, Koenders et al.
2004). Polyclonal anti-IL-17A antibodies also suppressed exacerbation of antigen-induced knee
swelling, proteoglycan depletion, and bone erosion in experimental RA model systems upon
reintroduction of the antigen (Koenders, Lubberts et al. 2005). The Th1 and Th2 cell lineages,
of which the Th1 cell phenotype resembles that of Th17 cells, have interestingly proven to
counteract the effect of Th17 cells on osteoclastogenesis, both in vitro and in experimental and
idiopathic conditions of rheumatoid arthritis (Aarvak, Chabaud et al. 1999).
4.2. T-helper 17 cells in Rheumatoid Arthritis (RA)
A multitude of experimental reports point to Th17 cell mediated inflammation being associ‐
ated with RA. IL-17A protein is located in both the synovium and the synovial fluid of pa‐
tients suffering from the disease. It was also demonstrated that a subset of T-cell lines could
be expanded in vitro from their RA synovium, which expresses both IL-17A and IFNγ [(Aar‐
vak, Chabaud et al. 1999; Pene, Chevalier et al. 2008). Classical IFNγ-only Th1 cells were al‐
so present, constituting a clonal species which can be expanded from the RA synovium
(Aarvak, Chabaud et al. 1999; Yamada, Nakashima et al. 2008). Exploratory medical studies,
however, not only establish the association of IL-17A with disease development, but also
implicate IL-17A with poor disease prognosis. The IL-17A message in synovial membrane
biopsies was one factor (including TNF, IL-1β, and IL-10) being predictive for subsequent
bone erosion and joint damage, as assessed by NMR imaging and X-ray analyses (Kirkham,
Lassere et al. 2006). Taken together, these data support the notion that IL-17A is present in
the inflamed synovium and that the levels of IL-17A expression correlate with poor progno‐
sis and greater joint destruction. All in all, Th17 cells secrete master factors that can directly
and indirectly drive osteoclast differentiation and activation. It is, however, a consensus in
the field of T-cell research that signature cytokines of the Th1, Th2, and Treg lineages inhibit
Th17 cell development. Therefore, one has construed that osteoclastogenesis is inhibited by
the same Th1, Th2, and Treg lineage signature cytokines counteracting the stimulatory po‐
tential of the cytokine mixture secreted by the Th17 cells (Adamopoulos, Sabokbar et al.
2006; Adamopoulos and Bowman 2008). Contrastingly, when comparing clonal cells lines,
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Th1 cells may resemble Th17 cells, questioning the postulate that the Th1 cell lineage consis‐
tently will counteract the impact of Th17 cells. In some instances, infiltration by Th1 cells
may even potentiate the detrimental effect of Th17 cells on the cartilage and bone in affected
joints (Yssel et al., unpublished data).
Figure 5. A. Effect of microRNA manipulations and cytokines on human osteochondral cells and osteoclasts injected
into the tibial muscle of SCID mice. X-ray and tissue histology of the lower leg (m. tibialis) from SCID mice. Each tibial
muscle was injected with hMSCs (2.5 million cells) and osteoclasts (0.5 million cells). Yellow, blue and red stars indicate
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that X-ray analyses and histology (visual parameters) were not significantly altered when cells were manipulated by
cytokines (IL-1, IL-6, IL-17, and TNFα). However, molecular parameters were dramatically changed. X-ray analyses and
histology were performed on excised legs 21 days subsequent to cell deposition. B. Differentiated chondrocytes (21
days) exposed to cytokines (initial 14 days) or pre-microRNAs (initial 14 days) and osteoclasts injected into the tibial
muscle of SCID mice. Molecular markers of chondrocytes and osteoclasts (PBMCs differentiated for 10 days) were ana‐
lysed by Q-PCR or colorimetric methods (GAG = glucosaminoglycan/DNA). Nd = Not determined. All values are given
relative to control conditions (chondrocytes alone or chondrocytes + osteoclasts). C. Differentiated osteoblasts (21
days) exposed to cytokines (initial 14 days) or antago-microRNAs (initial 14 days) and osteoclasts were injected into
the tibial muscle of SCID mice. Molecular markers of osteoblasts and osteoclasts (PBMCs differentiated for 10 days)
were analysed by Q-PCR or colorimetric methods (Ca2+-analyses in HCl-extracts). All values are given related to control
conditions (osteoblasts alone or osteoblasts + osteoclasts).
5. Cell-to-cell communication through exosomes
Cell-to-cell communication is required to guarantee proper coordination among different cell
types within tissues. Cells may communicate by soluble factors (Majka, Janowska-Wieczorek
et al. 2001), adhesion molecule mediated cell-to-cell interactions including cytonemes con‐
necting neighbouring cells enabling ligand–receptor-mediated transfer of surface-associated
molecules, or by tunnelling nanotubules which establish conduits between cells. These would
allow the transfer of both surface molecules and cytoplasmic components (Rustom, Saffrich et
al. 2004; Sherer and Mothes 2008). Recently published studies have suggested that cells may
also communicate by spherical membrane fragments called micro-vesicles (MVs) or exosomes
(Ratajczak, Wysoczynski et al. 2006). MVs or exosomes were since long considered to be inert
cellular debris, and the frequently observed vesicles by electron microscopy in the interstitial
space of tissues or in blood were considered the consequence of cell damage or a result of
dynamic plasma membrane turnover (Siekevitz 1972). It was suggested that the circular
plasma membrane fragments released from human cells might possibly result from a specific
process, and it was shown that they carried functional membrane enzymes in the same ratio
as the membrane of the cells they originated from (De Broe, Wieme et al. 1977). However, only
a few recent studies have assigned a defined function to the vesicles/exosomes released to the
microenvironment by various cell types. Two distinct processes of shedding vesicles from the
cells have been described. MVs may originate from the endosomal membrane compartment
that, subsequent to fusion with the plasma membrane, is extruded from the cell surface of
activated cells as exosomes (Heijnen, Schiel et al. 1999; Rozmyslowicz, Majka et al. 2003).
Otherwise, MVs may take origin by direct budding from the cell plasma membrane as
shedding vesicles (Cocucci, Racchetti et al. 2009).
Released MVs may remain in the extracellular space in the proximity of the place of origin, or
they may enter into the circulation. One has hypothesized that, under normal healthy condi‐
tions and disease states, micro-vesicles contain microRNAs, contributing to biological homeo‐
stasis in general (Hunter, Ismail et al. 2008; Gordeladze, Djouad et al. 2009; Gordeladze 2011).
It may also be hypothesized that MVs or exosomes, when present in disproportional amounts
within a tissue during development of certain diseases, in fact may affect all adjacent cell types,
thus altering their phenotypes and main functional properties (Camussi, Deregibus et al. 2010).
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 Figure 6. A. The effect of exosomes-containing 100,000xg fractions of supernatants derived from activated human
Th17 cells on human chondrocytes and osteoblasts in the presence and absence of osteoclasts. Chondrocytes
(500,000 cells) derived from hMSCs were either exposed to 1 ml volume containing exosomes from 250,000 Th-17
cells or pre-microRNA 222 (which is highly expressed in Th17 cells, but not in chondrocytes) and analysed for marker
gene and microRNA expressions using standard Q-PCR methods (Ambion) or immunohistochemistry (aggrecan and
collagen2α1 positive surfaces). Osteoblasts (500,000 cells) derived from hMSCs were either exposed to 1 ml volume
containing exosomes from 250,000 Th-17 cells or pre-microRNA 22 (which is highly expressed in Th-17 cells, but not in
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osteoblasts) and analysed for marker gene and microRNA expressions using standard Q-PCR methods (Ambion) or col‐
orimetric methods (mineralized surface visualized by Alizarin red S). B. The effect of exosomes-containing 100,000xg
fractions of supernatants derived from activated human Th17 cells on human chondrocytes and osteoblasts in the
presence and absence of osteoclasts. Differentiated osteoblasts (21 days) exposed to exosomes from Th17 cells (initial
14 days) or antago-microRNAs (initial 14 days) and osteoclasts were injected into the tibial muscle of SCID mice, and
molecular markers of osteoblasts and osteoclasts (PBMCs differentiated for 10 days) were analysed by Q-PCR or colori‐
metric methods (Ca2+-analyses in HCl-extracts). All values are given related to control conditions (osteoblasts alone or
osteoblasts + osteoclasts).
In one publication, it was shown that exosomes from healthy volunteers matched mononuclear
cells and contained 420 known mature microRNAs (Hunter, Ismail et al. 2008). Hierarchical
clustering of the data sets pointed to significant differences in microRNA expression between
peripheral blood mononuclear cells (PBMCs) and plasma micro-vesicles. It was observed that
71 microRNAs co-expressed between micro-vesicles and PBMCs. Prediction of the gene targets
and associated biological pathways regulated by the detected microRNAs demonstrated that
the majority of these microRNAs expressed in the micro-vesicles from the blood were pre‐
dicted to regulate the differentiation of blood cells and their metabolic pathways (Hunter,
Ismail et al. 2008). Interestingly, a small group of these microRNA species were also predicted
to serve as important modulators of immune function. The microRNAs in question were
hypothesized to be taken up by adjacent cells, and thus it may be asserted that exosomes from
Th17 cells, known to be present in vast numbers in articular fluid of patients with rheumatoid
arthritis (Adamopoulos and Bowman 2008; Nakashima and Takayanagi 2009; Raggatt and
Partridge 2010; Nakashima, Hayashi et al. 2012) with rheumatoid arthritis, may disturb the
phenotypic characteristics of osteochondral cells in inflamed joints.
6. Results and discussion
6.1. How does the osteochondral microRNA profile work?
In Fig. 1, we have presented a microRNA signature, consisting of six microRNA species.
These species have been selected amongst microRNAs putatively targeting one or several
of 14 transcription factors (TFs) deemed important for osteoblast differentiation from stem
cells  or precursor cells  (Gordeladze,  Djouad et  al.  2009).  It  was shown through reporter
constructs, that nine of these 14 TFs were targeted by the six microRNAs. Literature studies
further  indicated that  mir-149,  and possibly  also  mir-24,  may serve  as  a  switch  mecha‐
nism instrumental in determining whether stem cells will become osteoblasts or chondro‐
cytes  by  interfering  with  activators,  inhibitors  and  associated  proteins  instrumental  in
modulating the effects  of  Sox9 and Runx2 (lee legend to Fig.  1).  These two TFs oppose
each other  when it  comes  to  differentiation  of  stem cells  or  progenitor  cells  to  become
mature osteoblasts and chondrocytes (Marie 2008; Gordeladze, Djouad et al. 2009).
A bioinformatics study (see Fig. 2, A-C), using the Mir@nt@n algorithm (Le Bechec, Portales-
Casamar et al. 2011), showed that the microRNA species mir-149, mir-328, and mir-339 in
particular seemed to serve important regulatory roles when looking at some important criteria
for osteoblastogenesis. (A) JUN = transcription factor AP-1, known to be mandatory for
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osteoblast differentiation (Gordeladze, Djouad et al., 2009), appears to exert a major impact on
mir-339, and mir-149 in a hierarchical feed-forward fashion. (B) ETS1 and SP3, two of the 14
TFs constituting the selection criteria for the osteochondral microRNA profile (Gordeladze,
Reseland et al., 2011), appeared to serve as inductors of several microRNAs, among which we
find the microRNA species mir-149, mir-328, and mir-339. However, ETS1 and SP3 (along with
SP1 and SP7 = Osterix) are up-regulated in osteoblastic cells. Hence, the positive control exerted
by ETS1 and SP3 may be counterproductive, or maybe not? (C) In a more complicated
hierarchical feed-forward network, it can be noted that Sox9, an important regulator of
chondrogenesis, actually serves as a master regulator of mir-149 and mir-328, which both are
up-regulated in chondrocytes. When modelling the osteochondral microRNA profile with all
know factors of the canonical WNT-pathway (using all factors from the KEGG’s pathway), a
stunningly close interaction between some of the microRNA species of the profile and factors
discerning the osteoblast from the chondrocyte phenotypes emerged.
It may therefore be postulated that the presently described osteochondral microRNA profile
serves as a discriminator between osteoblasts and chondrocytes, and can be used as such in
the process of cell engineering, while the microRNAs published as markers for osteoblasts by
G. Stein and his collaborators distinguish osteoblasts from all other cell phenotypes in a
comprehensive manner (Li, Hassan et al. 2008; Hassan, Gordon et al. 2010; Zhang, Xie et al.
2011).
6.2. Summary of experiments proving the functionality of the osteochondral microRNA
profile
In Fig. 3, we list the results of some experiments where the endogenous levels of each micro‐
RNA species of the profile are altered. These experiments indicate that chondrocytes show
optimal microRNA profile levels, since some 6-8 fold increase do not alter their characteristics,
subsequent to differentiation from hMSCs. A reduction to 12-14% of their endogenous levels
shows that mir-16, mir-125b, mir-328, and mir-339 are necessary for chondrogenesis, while
mir-24 and mir-149 are not. Contrastingly, enhancing the endogenous levels of all the micro‐
RNA species in hMSCs more or less block their differentiation towards the osteoblast lineage.
As expected, reducing their levels in hMSCs by a factor of 2-2.5 clearly fortified their phenotype
as osteoblasts. This experiment establishes the six microRNAs as instrumental in osteochon‐
dral differentiation, while mir-24 and mir-149 play a dual role, being able to simultaneously
block osteoblastogenesis and stimulate chondrogenesis. An explanation for this dual role has
been sought in the information conveyed in Figs. 3A&B, looking for published data on their
known targets, as well as bioinformatics profiles, i.e. positions in feed-forward interaction
networks (see legend to Fig. 3).
6.3. Osteochondral cells influence osteoclasts: The impact of cytokines
In Fig. 4A, we depict a co-culture system where hMSCs are differentiated towards osteochon‐
dral cells for 2 weeks and co-cultured with differentiated osteoclasts on dentine for a third
week. The osteoclasts have been differentiated from hPBMCs for 1 week with RANK-L and
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M-CSF. It is clear that chondrocytes do stimulate osteoclasts to resorb bone, and that exposure
of the chondrocytes to cytokines (“artificial” synovial fluid from individuals with rheumatoid
arthritis = RA, i.e. growth medium containing IL-1, IL-6, IL-17A and TNFα) enhances the
osteoclasts’ bone resorbing potential.
6.4. MicroRNA manipulation of osteochondral cells: Obliteration of the impact of cytokines
In Figs. 4B&C it is shown that TGFβ3-stimulated hMSCs to chondrocytes or BMP2-stimulated
hMSCs to osteoblasts exposed to cytokines in fact are protected against loss of phenotypes and
normalize (i.e. reduce) their ability to enhance osteoblast activity upon normalization of their
endogenous microRNA profile. The tables show data for Q-PCR of phenotype marker genes,
RANK-L and OPG (counteracting each other), functional markers like clinical score (consti‐
tuted by chondrocyte bead histology, immunohistochemistry, distance between cells, GAG-
contents), mineralizing surface, percentage of TRAP-positive cells containing ≥ 3 nuclei, eroded
dentine surface (%), as well as Q-PCR of microRNAs of the osteochondral signature.
6.5. In vivo model of osteochondral cells interacting with osteoclasts
In Fig 5A, X-ray pictures and biopsy histology of tibial muscles of SCID mice are shown. Their
muscle tissue has been injected with hMSCs, osteoblasts without and with the presence of
differentiated osteoclasts. The osteoblasts were either loaded with antago-microRNAs of the
osteochondral signature or not. Additional experiments where hMSCs or osteoblasts had been
exposed to cytokines alone or cytokines and antago-microRNAs together are not shown on
the figure. A similar experimental matrix was conducted (but not shown) with chondrocytes
differentiated from hMSCs. The pictures indicate that mature osteoblasts and osteoclasts are
able to build bone within the muscle tissue, and that a suppression of the endogenous levels
of the microRNA species of the osteochondral signature lead to enhanced mineralization of
osteoid produced.
When chondrocytes (see Fig. 5B) are pre-exposed to osteoblasts, it appears that the cells are
able to maintain their net cartilage-building potential, possibly by down-regulating their
cytokine-induced osteoclast-activating potential. The same phenomenon is also seen when
osteoblasts are injected into the m. tibialis of SCID mice.
Cytokines induce a reduction in osteoblast functions, while also enhancing osteoclast activa‐
tion resulting in a lessened bone deposit, while introduction of antago-microRNAs reverses
the action of cytokines towards maintenance of the bone-building capacity of the osteoblast
(see Fig. 5C). A special attention to the Q-PCR data on osteoclast specific markers (CT receptor,
TRAP, cathepsin K and CA II) analysed in the excised de novo bone tissue is warranted.
Furthermore, it should be emphasized that the X-ray analyses of the lower legs injected with
osteoblasts were corroborated analysing the Ca2+-contents in acid extracts/digests, using
standard spectrophotometry.
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6.6. The effect of exosomes derived from activated Th17 cells
Lastly, we shall address the hypothesis put forward that exosomes shedded from immune cells
may affect the characteristics of osteochondral cells. Th17 cell exosomes-like particles were
obtained from 100,000xg centrifugates of cultures of activated Th17 cells (Larsen, Arnaud et
al. 2011). The pellets were examined for microRNAs (micro-arrays), and 55 microRNA-species
were identified. Of these, hsa-mir-22- and hsa-mir-222 are especially interesting, since the
exosome-fraction contained large quantities of these, and because Th17 cell clones also
produced large quantities of the same microRNA species, and since osteoblasts and chondro‐
cytes expressed relatively low levels of the mir-22, and mir-222 species, respectively.
Fig. 6A depicts chondrocytes having been differentiated from hMSCs for 2 weeks receiving
control medium or control medium + Th17 cells derived exosomes or pre-microRNA mir-222
on days 15-21. Q-PCR of marker genes and microRNA transcripts, as well as collagen2α1-
positive surface analyses were conducted and showed that chondrocyte characteristics were
suppressed. The same experiment was conducted on hMSCs differentiated towards osteo‐
blasts in the absence or presence of Th17 cell exosomes or pre-microRNA mir-22, and pheno‐
type marker analyses (i.e. Q-PCR of marker gene transcripts and mineralized surface)
conducted. Not surprisingly, the osteoblast phenotype was suppressed due to both treatments.
This indicates that exosomes from Th17 cells contain microRNAs detrimental to the function‐
ing of mature chondrocytes and osteoblasts, and it may well be so that engineered osteochon‐
dral cells, deposited within a joint to replace damaged tissues, should be made resilient to
inflammatory cells to maintain their proper phenotypic functioning over time.
One experiment (see Fig. 6B) with osteoblasts, osteoclasts, exosomes and antago-microRNAs
of the osteochondral signature was performed on SCID mice, as envisaged earlier. X-rays (not
shown) and analyses on excised biopsies from the tibial muscle showed that exposure to Th17
cell exosomes hampered the development of the matrix-producing and mineralizing proper‐
ties of osteoblasts, while enhancing activating of adjacent osteoclasts. The introduction of
antago-microRNAs of the osteochondral signature did, however, reinstall the osteoblasts’
ability to produce bone, which was not degraded by osteoclasts. This phenomenon was
corroborated through analyses of the Ca2+-contents of the biopsies taken (see also text-Fig. 5B).
6.7. Other results obtained
The present series of experiments also addressed whether certain scaffold materials and their
3D-structures were better suited to produce osteochondral cells with a “true” (in vivo like)
phenotype being more robust and resilient towards provocations, such as chronic disease
states. Whether we used scaffolds, i.e. alginate beads instead of micro-pellets, or hydroxya‐
patite instead of 2D-growth, really did not matter. However, we did not use promising
scaffolds for osteoblast differentiation, like TiO2 or surfaces with an inverted profile of cellular
outer membrane surface nanostructures (Muys, Alkaisi et al. 2006; De Smet, Jaecques et al.
2007; Mazzola, Bemporad et al. 2011).
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6.8. General discussion of the findings presented
This report is more about experimental approaches and results speaking for themselves than
a lengthy discussion of their implications from a theoretical point of view. A few issues do,
nevertheless, deserve attention.
Most reports on microRNA impact on cell differentiation and phenotype development and
stability focus on one microRNA species only, or they present a microRNA micro-array
showing a bulk of microRNAs being up- and down-regulated subsequent to cell differentia‐
tion. Since microRNAs exert different binding kinetics when they bind to different mRNAs at
various places (not only to the 3’-UTR, but also to the 5’-UTR region) (Moretti, Thermann et
al. 2010), it is reasonable to believe that a minimum effective group of microRNAs is necessary
and sufficient to ensure complete differentiation and stability of a certain cell phenotype
(Gordeladze, Djouad et al. 2009; Iorio, Casalini et al. 2011; Schoof, Botelho et al. 2012). The
osteochondral signature of microRNAs presented in this chapter may serve as such a group,
discriminating between cell types, however, several other microRNA species described by G.
Stein and collaborators (Li, Hassan et al. 2009; Hassan, Gordon et al. 2010; Zhang, Xie et al.
2011) may serve the same purpose. In fact, our microRNA micro-arrays obtained from
osteoblastic cells in different stages of differentiation from hMSCs do overlap extensively to
the ones published in recent literature (Lian, Javed et al. 2004).
Which microRNAs are to be construed as the “true” marker for osteoblasts? They may
constitute more than the six species presented here, or even other than the ones we have
focussed on. The main issue is how they interact with feed-forward and feed-back regulatory
loops, in which transcription factors and marker genes are positioned. This issue has been
addressed in the bioinformatics exercises outlined in Fig. 2. Here, mir-26b pops up as being
important, and this microRNA is known to a network of factors serving as a possible target
for RNA-based therapy of bone diseases (Luzi, Marini et al. 2012). The main issue is: which
microRNAs out of a smaller group will be necessary and sufficient to determine or alter a
certain phenotype? Our experiments with the present osteochondral microRNA signature
seem to render one such microRNA group distinguishing between osteoblasts and chondro‐
cytes. A further proof of concept put forward is the fact that these microRNAs can be applied
to trans-differentiate osteoblastic cells to chondrocytes and back again, and they are also able
to a large extent (some 85%) substitute growth factors (TGFs and BMPs) as mandatory to obtain
chondrocytes and osteoblasts from hMSCs or human adipose tissue derived stem cells
(hADMSCs) (Gordeladze, JO, unpublished results).
In chapter 2 of the book “Regenerative Medicine and Tissue Engineering: Cells and BioMate‐
rials” (Gordeladze 2011), we introduced a concept of compatibility score between microRNA
micro-arrays and transcriptomes obtained from chondrocytes and osteoblasts differentiated
from precursor cells of stem cell origin (ref). We still believe that a proper way to ensure
“correct” phenotype is to correlate consensus micro-arrays of marker gene transcripts with
microRNA micro-arrays; however, such analyses were not performed on the present manip‐
ulated biological material. Due to relative meticulous experimentation consuming a lot of
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manpower, biological material and costly analyses, it was not performed. However, micro-
arrays analysed at certain intervals during a differentiation process may seem necessary to be
able to arrive at the superior microRNA profiles describing a certain cell phenotype to be
distinguished from other phenotypes.
One question pertaining to the assurance of a reproducible process of establishing engineered
cells with the “correct” phenotype is: Why play with microRNAs, is it not enough to manip‐
ulate using growth factors and the 3D-structure, in which the precursor cells are grown? Firstly,
it is important to know the interplay between factors able to induce a certain cell phenotype
and/or trans-differentiate phenotypes. In this respect, it seems fruitful to concentrate on several
microRNAs, and not only on one microRNA species. But, it is also reasonable to play with the
expression of certain transcription factors (TFs) being positioned in key places in a regulatory
network constituted by TFs, activators, inhibitors or associated proteins, as well as functional
marker genes. Sox9, a TF deemed sufficient and necessary for chondrocyte development (see
legend to Fig. 2C) may be over-expressed or suppressed to engineer chondrocytes or osteo‐
blasts, since it affects the expression of important microRNAs and marker genes in a hierarch‐
ical fashion. Apparently, so do ETS1 and SP3, or MYC and JUN (see legend to Figs. 2B&A).
However, it seems reasonable to believe that, at least during a shorter, critical period of time,
externally added growth factors and the selection of biologically “correct” scaffold structures
and materials will aid in the process of proper phenotype acquisition for tissue replacement
purposes. It has also been pointed out that it is vital, for a proper tissue to be generated, to use
cell material which can differentiate into several cell types constituting a certain tissue, or that
the engineered cell material is able to recruit cells from the ambiance to produce a correctly
functioning tissue in vivo. A good example of this seems to be an artificially made tracheal
epithelium, using collagen vitrigel-sponge scaffolds containing bFGF as growth factor and
chemotactic agent (Tani, Tada et al. 2012).
We  are  now  seeking  to  produce  polycistronic  constructs  containing  pre-microRNAs  or
antago-microRNAs to  be  temporarily  activated in  order  to  test  whether  the  microRNA-
based concept  of  cell  engineering may function in  an  in  vivo  animal  model  of  rheuma‐
toid arthritis, where articular joints are inflamed and contain immune cells (i.e. Th17 cells).
Hence,  we  will  be  able  to  find  out  whether  osteochondral  cells  may  be  engineered  to
withstand  the  detrimental  effect  of  cytokines  and  exosomes  containing  (amongst  many
bioactive molecules) unwanted microRNA species. Promising small animal models to start
with are collagen-induced arthritis in the mouse, and the senescence mouse (Aigner, Rose
et al. 2004; Manolagas and Almeida 2007) prior to the testing in larger animals (i.e. sheep
model systems) (Gordeladze, Reseland et al. 2009).
Lastly, the present experiments confirm the complexity of bone remodelling in the healthy
individual and in patients with diseases affecting cartilage and bone structure. Not only
hormones, like active vitamin D (calcitriol) and PTH affect bone turnover, via their dual effects
on osteoblasts and osteoclasts. The interaction with the immune system directly interfering
with the balance between RANK-L and OPG (Adamopoulos, Sabokbar et al. 2006; Nakashima,
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Hayashi et al. 2012), as well as cell-to-cell communication through exosomes, containing a
plethora of bioactive molecules, urges new research approaches to unravel the intricate
mechanisms ensuring bone and cartilage health before and after the onset of disease states
damaging the tissues in question. We have here confirmed that chondrocytes, in fact, do affect
osteoclasts directly (Xiong, Onal et al. 2011), and that cytokines obtained from Th-cells, and
Th17 cells in particular, are detrimental to the osteochondral phenotypes, with an additional
activation of osteoclasts.
The present experimental setting also show that exosomes from Th17 cells may interfere with
both the chondrocytic and osteoblastic phenotypes in a negative fashion (i.e. phenotype
acquisition and matrix deposition), while also speeding up bone remodelling via over-
activation of osteoclasts embedded in the bone adjacent to the cartilage lining. These findings
are consistent with the development of cartilage loss and the appearance of osteophytes (newly
formed bone in disarray) in arthritic joints due to the progressing autoimmune process
characteristic of rheumatoid arthritis (Hayashi, Xu et al. 2012).
7. Summary and future prospects
This particular report entails the use of transient microRNA manipulations to ensure acquis‐
ition of proper osteochondral phenotypes when engineering cells to replace damaged bone
and cartilage in patients with inflammatory diseases targeting articular joints (in particular
rheumatoid arthritis). We have shown that cell engineering, as a research field, needs to take
into consideration how osteochondral cells affect osteoclasts directly, and that osteochondral
cells may lose their acquired phenotypes upon exposure to cytokines (e.g. IL-1, IL-6, IL-17, and
TNFα) or micro-RNA-containing exosome-like particles derived from activated Th17 cells.
These detrimental effects can be counteracted by manipulating stem cell microRNA contents
(the optimal minimal number and species of microRNAs are yet to be defined).
When refining the search for the minimal number of effective microRNAs, it is recommended
that bioinformatics approaches are used along with micro-RNA micro-arrays and marker gene
transcriptomes in engineered osteochondral cells, and that maximal compatibility score
(Gordeladze 2011) between them are obtained. Assessment of phenotypes obtained should
include analyses of how and to which extent these cells affect osteoclasts, and whether altered
(i.e. enhanced) remodelling of bone formed within an in vivo model system (e.g. calcium
deposits in the tibial muscle of SCID mice) of choice.
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